TOP > News Release > list in 2009
- 2009.12.21
- Daiichi Sankyo to Leverage Ranbaxy's Presence in Africa for Marketing and Distribution Olmesartan to be launched in six African countries
- 2009.12.11
- Results of a Clinical Phase 3 Trial of an Oral Factor Xa Inhibitor, Edoxaban, in Prevention of Post-Operative Venous Thromboembolism
- 2009.11.09
- Regarding the Lawsuit to Revoke the Decision to Nullify a Portion of the Patent Term Extension for Levofloxacin in Japan
- 2009.10.30
- Differences between Consolidated Forecasts and Consolidated Results for the First Six Months of Fiscal Year Ending March 2010
- 2009.10.29
- Daiichi Sankyo Submits Application for Approval of Levofloxacin Hydrate Injection in Japan
- 2009.10.16
- Additional indication for the natural-type interferon beta preparation Feron(R) against "chronic hepatitis C on concomitant use with ribavirin"
- 2009.10.05
- Daiichi Sankyo to Leverage Ranbaxy's Presence in Mexico for Marketing and Distribution
New Division will bring Daiichi Sankyo's innovator products to Mexican market
- 2009.09.01
- Daiichi Sankyo and Ranbaxy Leverage New Business Model with Launch of EVISTA in Romania
- 2009.08.10
- Positive top line results from Phase III study (MARVEL) of anti-influenza virus agent 'CS-8958'
- 2009.08.10
- Notice of Postponement of Open Offer for Shares in Zenotech Laboratories Limited
- 2009.08.03
- THE U.S. DISTRICT COURT HAS ISSUED A DECISION IN OUR FAVOR IN OUR U.S. PATENT LITIGATION REGARDING BENICAR(R), BENICAR HCT(R) AND AZOR(R)
- 2009.07.31
- DAIICHI SANKYO to Issue Stock Options (Stock Acquisition Rights) as Remuneration
- 2009.07.16
- ANALYSIS OF EDOXABAN PHASE II DATA PROVIDES INSIGHT INTO REDUCED BLEEDING EVENTS SEEN IN ONCE-DAILY DOSING
- 2009.07.13
- Daiichi Sankyo's Research Foundation Establishes
Second Annual Clinical Pharmacology Research Award
- 2009.05.28
- Partial Correction to Consolidated Financial Results for the Fiscal Year Ended March 31, 2009 (Correction of Figures)
- 2009.05.24
- Daiichi Sankyo and Ranbaxy Announce Reconstitution of Ranbaxy Executive Leadership
